Efficacy and Safety of Aflibercept 8 mg in PULSAR Trial in Neovascular AMD

Opinion
Video

Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.

Newsletter

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Subscribe Now!
Recent Videos
At ARVO 2025, Christine Kay, MD, shares interim results from the PRISM trial population extension cohort
Related Content
Anonymous $40 million gift received by University of Colorado Anschutz Medical Campus Ophthalmology Department

Anonymous $40 million gift received by University of Colorado Anschutz Medical Campus Ophthalmology Department

Martin David Harp
June 10th 2025
Article
Brazil’s ANVISA grants marketing authorization to Lucentis biosimilar FYB201 (Ranivisio, Formycon/Bioeq AG)

Brazil’s ANVISA grants marketing authorization to Lucentis biosimilar FYB201 (Ranivisio, Formycon/Bioeq AG)

Lynda Charters
June 8th 2025
Article
NIH scientists develop new surgical technique for grafting tissue in the retina

NIH scientists develop new surgical technique for grafting tissue in the retina

Kassi Filkins
May 29th 2025
Article
NASA astronauts to keynote 2025 International SPECTRALIS Symposium in Heidelberg

NASA astronauts to keynote 2025 International SPECTRALIS Symposium in Heidelberg

Hattie Hayes
May 27th 2025
Article
Lineage to announce data from phase 1/2a study on use of RG6501

Lineage to announce data from phase 1/2a study on use of RG6501

Kassi Filkins
May 20th 2025
Article
Positive interim phase 2 results for MGB

Positive interim phase 2 results for MGB

Kassi Filkins
May 19th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.